[Bisphosphonates (BP) and osteonecrosis of the jaws; continuous treatment with Bisphosphonates should be considered].
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University.
Taro
T
Mawatari
D000284:Administration, Oral; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D007571:Jaw Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D010020:Osteonecrosis / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D010024:Osteoporosis / Q000188:drug therapy; D058866:Osteoporotic Fractures / Q000453:epidemiology / Q000517:prevention & control*; D011379:Prognosis; D011788:Quality of Life; D012306:Risk; D018570:Risk Assessment
D050071:Bone Density Conservation Agents; D004164:Diphosphonates